Search
for
Sort by
Research 151–180 of 1000+
- INTERFERONS IN DERMATOLOGY
- Prevalence of Skin Conditions Among Pediatric Patients in the Region of Istanbul
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Janus Kinase inhibitors in dermatology: a review
- Farmácia Padrão da Légua, Custóias e nos Serviços Farmacêuticos da Klinicka Bolnica Dubrava, Croácia
- State of the art of photobiomodulation in Dermatology
- CARACTERÍSTICAS CLÍNICAS E EPIDEMIOLÓGICAS DO EFLÚVIO TELÓGENO PÓS COVID-19
- Most frequent dermatosis in patients with kidney transplantation
- Tofacitinib: The selected selective JAK inhibitor in paediatric dermatology
- PRESEPTAL CELLULITIS DUE TO IMPETIGO – A CASE REPORT OF UNCOMMON PRESENTATION IN PAKISTAN
- Psychosocial Aspects of Skin Conditions and Diseases
- Pattern of Skin disorders across age groups
- Description of skin lesions
- Subject Index
- Principles of Therapy of Skin Diseases
- American Academy of Dermatology
- Viewpoint 1
- Madarosis, milphosis, eyelash trichomegaly, and dermatochalasis
- Skin Disorders in Athletes: Professional and Recreational Sports
- Mucocutaneous reactions to chemotherapy
- Index
- A Phase 1, Open‐Label Study of the Pharmacokinetics of Ritlecitinib in Children Aged 6–12 Years With Alopecia Areata
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- A scoping review of alopecia areata and its relationship to COVID-19 vaccinations
- Alopecia Areata Occurring after COVID-19 Vaccination: A Single-Center, Cross-Sectional Study
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial
- A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata
- Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
- Ritlecitinib for Severe Alopecia Areata: A 24-Week, Multicentre, Real-World Study